BIIB BIOGEN INC revenue, earnings and financials
For the quarter ended June 30, 2026, BIOGEN INC reported revenue of $2.74B (up 3.4% from a year earlier), net income of $97.5M and diluted EPS of $0.66; over the last four quarters revenue was $10.0B and net income $835M; for the fiscal year ended December 2025 revenue was $9.89B, up 2.2% on the year before.
BIIB annual revenue and earnings
- Fiscal year ended Dec 2025: revenue $9.89B, gross profit n/a, operating income n/a, net income $1.29B (margin 13.1%), EPS $8.79
- Fiscal year ended Dec 2024: revenue $9.68B, gross profit n/a, operating income n/a, net income $1.63B (margin 16.9%), EPS $11.18
- Fiscal year ended Dec 2023: revenue $9.84B, gross profit n/a, operating income n/a, net income $1.16B (margin 11.8%), EPS $7.97
- Fiscal year ended Dec 2022: revenue $10.2B, gross profit n/a, operating income n/a, net income $3.05B (margin 30.0%), EPS $20.87
- Fiscal year ended Dec 2021: revenue $11.0B, gross profit n/a, operating income $2.84B, net income $1.56B (margin 14.2%), EPS $10.40
BIIB quarterly revenue and earnings
- Quarter ended Jun 30, 2026: revenue $2.74B (up 3.4% year over year), net income $97.5M, EPS $0.66
- Quarter ended Mar 31, 2026: revenue $2.48B (up 1.9% year over year), net income $320M, EPS $2.15
- Quarter ended Dec 31, 2025 (from the annual report): revenue $2.28B (down 7.1% year over year), net income −$48.8M, EPS −$0.35
- Quarter ended Sep 30, 2025: revenue $2.53B (up 2.8% year over year), net income $467M, EPS $3.17
- Quarter ended Jun 30, 2025: revenue $2.65B (up 7.3% year over year), net income $635M, EPS $4.33
- Quarter ended Mar 31, 2025: revenue $2.43B (up 6.1% year over year), net income $241M, EPS $1.64
- Quarter ended Dec 31, 2024 (from the annual report): revenue $2.45B (up 2.9% year over year), net income $267M, EPS $1.82
- Quarter ended Sep 30, 2024: revenue $2.47B (down 2.5% year over year), net income $389M, EPS $2.66
- Quarter ended Jun 30, 2024: revenue $2.46B (up 0.4% year over year), net income $584M, EPS $4.00
- Quarter ended Mar 31, 2024: revenue $2.29B (down 7.0% year over year), net income $393M, EPS $2.70
- Quarter ended Dec 31, 2023 (from the annual report): revenue $2.39B (down 6.2% year over year), net income $250M, EPS $1.70
- Quarter ended Sep 30, 2023: revenue $2.53B (up 0.9% year over year), net income −$68.1M, EPS −$0.47
- Quarter ended Jun 30, 2023: revenue $2.46B (down 5.1% year over year), net income $592M, EPS $4.07
- Quarter ended Mar 31, 2023: revenue $2.46B (down 2.7% year over year), net income $388M, EPS $2.67
- Quarter ended Dec 31, 2022 (from the annual report): revenue $2.54B (down 6.9% year over year), net income $551M, EPS $3.73
- Quarter ended Sep 30, 2022: revenue $2.51B (down 9.7% year over year), net income $1.13B, EPS $7.84
- Quarter ended Jun 30, 2022: revenue $2.59B (down 6.7% year over year), net income $1.06B, EPS $7.24
- Quarter ended Mar 31, 2022: revenue $2.53B (down 6.0% year over year), net income $304M, EPS $2.06
- Quarter ended Dec 31, 2021 (from the annual report): revenue $2.73B, net income $368M, EPS $2.50
- Quarter ended Sep 30, 2021: revenue $2.78B, net income $329M, EPS $2.22
BIIB cash flow, buybacks and dividends
- Fiscal year ended Dec 2025: operating cash flow $2.20B, share buybacks n/a
- Fiscal year ended Dec 2024: operating cash flow $2.88B, share buybacks $0
- Fiscal year ended Dec 2023: operating cash flow $1.55B, share buybacks $0
- Fiscal year ended Dec 2022: operating cash flow $1.38B, share buybacks $750M
- Fiscal year ended Dec 2021: operating cash flow $3.64B, share buybacks $1.80B
BIIB balance sheet
- Jun 30, 2026: cash n/a, total assets $32.1B, total liabilities $13.2B, shareholders' equity n/a
- Mar 31, 2026: cash n/a, total assets $29.5B, total liabilities $10.8B, shareholders' equity n/a
- Dec 31, 2025: cash n/a, total assets $29.4B, total liabilities $11.2B, shareholders' equity n/a
- Sep 30, 2025: cash n/a, total assets $29.2B, total liabilities $11.0B, shareholders' equity n/a
- Jun 30, 2025: cash n/a, total assets $28.3B, total liabilities $10.7B, shareholders' equity n/a
- Mar 31, 2025: cash n/a, total assets $28.0B, total liabilities $11.1B, shareholders' equity n/a
- Dec 31, 2024: cash n/a, total assets $28.0B, total liabilities $11.3B, shareholders' equity n/a
- Sep 30, 2024: cash n/a, total assets $28.3B, total liabilities $12.0B, shareholders' equity n/a
What is BIIB's revenue?
BIOGEN INC reported $10.0B of revenue over its last four quarters, through June 30, 2026.
Is BIIB profitable?
Yes. BIOGEN INC earned $835M over the last four quarters.
What is BIIB's EPS?
Diluted earnings per share over the last four quarters were $5.63; $0.66 in the latest quarter.